EN
Home/Canada/Blog/Which generic versions of Ozempic and Wegovy are approved in Canada?
CACanada Medicines

Which generic versions of Ozempic and Wegovy are approved in Canada?

Every generic semaglutide product Health Canada has approved, what it copies, and whether it was on the market when we checked the Drug Product Database.

GLP Guidebook teamPublished 12 Oct 202610 min read21 sourcesWritten from published sources

Written for Canada. Reading from India? India version

The short answer

As of 12 October 2026, Health Canada has approved five generic copies of Ozempic, from Dr. Reddy’s, Apotex, Aspen (two) and Sandoz, plus Sevmia, a generic of Wegovy. Only the Dr. Reddy’s and Apotex Ozempic copies were marketed. All are prescription-only, and the Ozempic copies are approved for type 2 diabetes.

Key takeaways

  • Health Canada had approved six generic semaglutide products by 12 October 2026: five copies of Ozempic for type 2 diabetes and one, Sevmia, copying Wegovy.1
  • Only Dr. Reddy’s Semaglutide Injection and Apo-Semaglutide Injection were marketed on 12 October 2026; both reached pharmacies in May 2026.1,2
  • Generics became possible after data protection on Ozempic ended on 4 January 2026, according to Health Canada’s Register of Innovative Drugs.3
  • The generic pens deliver the same 0.25, 0.5 and 1 mg doses as Ozempic, but no generic has a 2 mg pen.4,5,6
  • Ontario’s drug plan lists generic semaglutide at $78.14 a pen, against $227.94 for an Ozempic pen.7
Before you go further
  • GLP‑1 medicines are prescription drugs in Canada. Nothing here is a reason to start, stop or switch one.1
  • We name brands and official prices as facts. We don’t recommend, rank or link to any brand, pharmacy, clinic or program.
  • Ozempic, its generics and Mounjaro are approved for type 2 diabetes. Using them for weight loss is off-label (outside the approved use).6,8
  • The risks are the same however you get the medicine: see our side effects guide.
On this page
  1. Why could Canada approve generic semaglutide before other G7 countries?
  2. Which generics are approved, and which are on the market?
  3. Can a pharmacy fill a generic prescription today?
  4. Is a generic the same as Ozempic?
  5. What does a generic pen cost?
  6. Can generic semaglutide be used for weight loss?
  7. Questions people ask
  8. How we researched this
  9. Sources

Why could Canada approve generic semaglutide before other G7 countries?

Ozempic’s data protection in Canada ended on 4 January 2026, and its main Canadian patent had already lapsed, so generic makers could file.3,9

When a new medicine is approved, Health Canada protects the maker’s trial data for a set time. For semaglutide, the Register of Innovative Drugs lists that protection ending on 4 January 2026.3

The patent went earlier. Benefits and Pensions Monitor reported in June 2025 that Novo Nordisk did not pay a $450 maintenance fee on the Canadian patent, which then lapsed. Novo Nordisk said there was “no mistake”.9

Health Canada approved the first generic, from Dr. Reddy’s, on 28 April 2026, and called Canada “the first G7 country” to do so. It said it was reviewing eight other generic submissions at the time.10

Which generics are approved, and which are on the market?

Six generic products from four companies are approved; two are marketed. Status from Health Canada’s Drug Product Database, checked 12 October 2026.1

Product (company)CopiesApproved forStatus on 12 Oct 2026
Semaglutide Injection Dr. Reddy’sOzempicType 2 diabetesMarketed since 6 May 2026
Apo-Semaglutide Injection ApotexOzempicType 2 diabetesMarketed since 14 May 2026
Sevmia ApotexWegovyWeight management; lowering heart-attack riskApproved 29 Jun 2026, not marketed
Aspen-Semaglutide AspenOzempicType 2 diabetesApproved 17 Jul 2026, not marketed
Semaglutide Injection AspenOzempicType 2 diabetesApproved 25 Aug 2026, not marketed
Sandoz Semaglutide SandozOzempicType 2 diabetesApproved 16 Sep 2026, not marketed

Listed by approval date, not ranked. “Marketed” is the Drug Product Database’s status for a product the company has started selling. Source: Health Canada Drug Product Database; product monographs.

Sources for each row: the database records1 and each product’s monograph or announcement.4,5,11,12 Sandoz said its approval would bring “no material contribution this year”, and gave no launch date.12

Plosbrio and Poviztra are not generics. They are Novo Nordisk’s own extra semaglutide brands. Both are listed as approved and not marketed.1

Can a pharmacy fill a generic prescription today?

Often, but supply has been patchy. The two marketed generics arrived in May 2026, and Dr. Reddy’s reported a shortage in July.2,13

Apotex began shipping on 19 May 2026, and Dr. Reddy’s product had reached “select” pharmacies by then. A supply group warned that “availability may vary across regions”.2

On 10 July 2026, Dr. Reddy’s reported a shortage caused by a manufacturing disruption, Alberta Blue Cross said.13 In August, some Dr. Reddy’s and Apotex lots were recalled: see generic semaglutide recalls in 2026.14,15

Your pharmacist can tell you which product they have in stock. Approval doesn’t mean a product is on the shelf.

Is a generic the same as Ozempic?

Same medicine, same doses and the same approved diabetes uses. It is made a different way, and it comes in a different pen.4,5,6

Same medicine. Each contains semaglutide, a copy of a gut hormone called GLP‑1. It helps the body release insulin when blood sugar is high, and slows how fast the stomach empties. The Dr. Reddy’s and Apotex monographs list the same type 2 diabetes uses as Ozempic’s.4,5,6

Made differently. Ozempic is made using yeast (“recombinant DNA technology”). The generics are “produced by solid-phase synthetic chemistry”.6,4,5

Different pens. The generic pens deliver 0.25 or 0.5 mg, or 1 mg. Ozempic also has a pen for 2 mg doses; no generic does.4,5,6 The generic leaflets say: “Do not count the pen clicks.” Use the dose counter instead.4,5

Interchangeable on drug plans. Ontario, Alberta and Saskatchewan list the generics as interchangeable with Ozempic. That lets a pharmacy dispense one for the other under plan rules.7,13,16

Free toolWork out a 6- or 12-month cost

Pick a medicine and a dose plan, then add what your plan pays. No sign-up.

Open the calculator

What does a generic pen cost?

Ontario’s drug plan lists a generic pen at $78.14, about a third of Ozempic’s $227.94, and it pays the generic price for both.7

Each pen holds 4 weekly doses.4,5 A year of weekly doses is 13 pens: about $1,016 at the Ontario generic price, or $2,963 at the Ozempic price (our arithmetic).7

The gap is close to the top tier of the national generic pricing framework, which prices a non-oral generic at 35% of the brand once three or more generics exist.17 $78.14 is 34% of $227.94, although only two generics were marketed; we found no published explanation of how Ontario set it. Health Canada says many generics cost “45 to 90%” less than the brand.10

Pharmacies set their own cash prices, so what you pay can differ. Prices in more detail: GLP‑1 prices in Canada.

RisksThe risks, in brief
  • Stomach effects. In the diabetes trials in Ozempic’s Canadian monograph, about 17 in 100 people on 0.5 mg felt sick (nausea), and 20 in 100 on 1 mg. On comparison treatments it was about 6 in 100.6
  • Gallstones. About 7 in 1,000 people on 0.5 mg and 11 in 1,000 on 1 mg, against 5 in 1,000 on comparison treatments.6
  • Pancreatitis (an inflamed pancreas): confirmed in 0.3 cases per 100 patient-years on Ozempic in the diabetes trials, against 0.2 on another GLP‑1 medicine and none on a dummy injection or other diabetes medicines. The warning sign is severe stomach pain that won’t go away, sometimes spreading to the back.6,18
  • Low blood sugar is more likely if you also take insulin or a sulfonylurea such as gliclazide.18
  • Thyroid. Semaglutide must not be used if you or a family member has had medullary thyroid cancer, or if you have MEN 2.6
Full detail in our side effects guide →
Get help now: call 911 or go to the nearest emergency department for severe stomach pain that won’t go away, with or without vomiting. It can be pancreatitis. Not sure? Call 811 to speak to a nurse in most provinces (Info-Santé 811 in Quebec).18,19

Can generic semaglutide be used for weight loss?

The five Ozempic copies are approved for type 2 diabetes only, so using them for weight is off-label. Sevmia is the one generic approved for weight management.4,5,11

A prescriber can prescribe off-label on their own judgment. Canada’s obesity guideline discourages using medicines “solely for obesity management if they lack regulatory approval for this indication”.20

Drug plans draw the same line. Saskatchewan’s plan says the generics “will not be considered for off label uses, including chronic weight management”.16 Why no province covers weight-loss GLP‑1s: the CDA-AMC and pCPA story.

Sevmia’s pen only gives 1 mg doses. See what Sevmia is.21

Questions people ask

Is there a generic Ozempic in Canada?

Yes. Health Canada has approved five generic copies of Ozempic. On 12 October 2026, the Dr. Reddy’s and Apotex products were marketed; the Aspen and Sandoz ones were approved but not yet marketed.1

Is Apo-Semaglutide the same as Ozempic?

It has the same medicine, doses and diabetes uses. It is made by chemical synthesis rather than in yeast, and its pen has no 2 mg option. Ontario lists it as interchangeable with Ozempic.5,6,7

Is there a generic Wegovy in Canada?

Sevmia, from Apotex, was approved on 29 June 2026 as a generic of Wegovy. It was not marketed on 12 October 2026.1,11

Is there a generic Mounjaro in Canada?

No. Health Canada’s register lists data protection on tirzepatide, the medicine in Mounjaro, until 24 November 2030.3

Are Plosbrio and Poviztra generics?

No. They are extra semaglutide brands registered by Novo Nordisk itself. Both were approved but not marketed on 12 October 2026.1

How we researched this

We searched Health Canada’s Drug Product Database for every semaglutide product on 12 October 2026, and read each generic’s product monograph and the Health Canada announcements. Prices come from Ontario’s formulary, the only provincial list we found with a published price for each pen.

Availability changes month to month. Each status here is dated.

Before you move on

  • Check the brand name and DIN on your pack match your prescription.
  • Use the dose counter, not the clicks, on a generic pen.
  • Ask your pharmacist which product they stock before a refill.
  • Ask your plan whether it pays the generic price only.
  • Check the lot number against the August 2026 recalls.
Cost calculatorSide effects and risksType 2 diabetes reading path

More from the Canada blog

CACanadaHow much do Ozempic, Wegovy, Mounjaro and Zepbound cost in Canada?CACanadaWhat is Sevmia, the generic Wegovy, and when will it be available?CACanadaWhich generic semaglutide pens were recalled in Canada in 2026, and what should you do?
About GLP Guidebook

The monthly Canada update

An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: Health Canada approvals, recalls, provincial coverage changes and official prices. How we write

Was this post easy to understand?

Sources

  1. Health Canada. Drug Product Database: status records for every semaglutide product (Ozempic, Rybelsus, Wegovy, Plosbrio, Poviztra; generics from Dr. Reddy’s, Apotex, Aspen and Sandoz, and Sevmia). Searched 12 October 2026. Link
  2. Global News / The Canadian Press. Generic semaglutide sales begin in Canada. 20 May 2026. Link
  3. Health Canada. Register of Innovative Drugs, 24 January 2025 edition (semaglutide: data protection ends 2026-01-04; tirzepatide: data protection ends 2030-11-24). Link
  4. Dr. Reddy’s Laboratories. Semaglutide Injection Product Monograph, date of authorization 28 April 2026 (“Produced by solid-phase synthetic chemistry”; 2 mg and 4 mg pens; indications; storage; “Do not count the pen clicks”). PDF
  5. Apotex. Apo-Semaglutide Injection Product Monograph, date of authorization 1 May 2026 (synthetic; 0.25/0.5 mg and 1 mg pens; type 2 diabetes indications; storage). PDF
  6. Novo Nordisk Canada. Ozempic (semaglutide injection) Product Monograph, 13 July 2026 (produced by recombinant DNA technology in yeast; 2, 4 and 8 mg pens; indications; adverse reactions table; pancreatitis; contraindications). PDF
  7. Ontario Ministry of Health. Ontario Drug Benefit Formulary search, semaglutide rows (Ozempic $227.94 per pen with $78.141 paid; Apo-Semaglutide and Dr. Reddy’s $78.141; Sevmia $325.048, off-formulary interchangeable; Wegovy off-formulary interchangeable, no price; Rybelsus $7.5303 per tablet; no tirzepatide row). Checked 12 October 2026. Link
  8. Eli Lilly Canada. Mounjaro (tirzepatide injection) Product Monograph, date of authorization 23 June 2026 (type 2 diabetes in adults and in ages 10 to under 18; single-dose pen, vial and 4-dose KwikPen; storage). PDF
  9. Benefits and Pensions Monitor. Novo Nordisk to lose patent protection in Canada for Ozempic and Wegovy (unpaid maintenance fee). 18 June 2025. Link
  10. Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. News release, 28 April 2026. Link
  11. Apotex. Apotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight management. Press release, 30 June 2026. Link
  12. Sandoz. Sandoz receives regulatory approval for generic semaglutide in Canada. Press release, 18 September 2026. Link
  13. Alberta Blue Cross. Pharmacy Benefact 1330, July 2026 (generic semaglutide added to the Alberta Drug Benefit List from 1 July 2026, interchangeable with Ozempic; Dr. Reddy’s shortage reported 10 July 2026; LCA pricing postponed). PDF
  14. Health Canada recall. Semaglutide Injection (Dr. Reddy’s), DINs 02567806 and 02567814, lots 7000542, 7000543, 7000544, 7000545, 7000546, 7000624, 7000628 and 7000629: “An impurity is out of specification in all lots of the affected products.” Type II, retail level. 27 August 2026. Link
  15. Health Canada recall. Apo-Semaglutide (2 mg/pen), DIN 02568020, lot 7000599A: may “display a 2 mg dose in the dose window and deliver a 2 mg dose instead of the expected 0.25 mg or 0.5 mg dose.” Type II, retail level. 27 August 2026. Link
  16. Saskatchewan Blue Cross. Generic Ozempic in Saskatchewan: what it means for your clients and members (generics added to the Saskatchewan Drug Plan Formulary 1 July 2026, interchangeable, Exception Drug Status; “They will not be considered for off label uses, including chronic weight management”). 7 August 2026. Link
  17. Patented Medicine Prices Review Board (NPDUIS). Generic and biosimilar pricing policies: pCPA tiered framework (three or more generics: “25% … for oral solids; 35% for non-oral solids”). 15 January 2024. Link
  18. Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, date of authorization 2 October 2026 (indications; dose escalation; STEP 1–3 results and adverse reactions; pancreatitis, gallbladder, kidney and pregnancy warnings; storage). PDF
  19. Heart and Stroke Foundation of Canada. Medical services by phone (811 in most provinces and Yukon; Info-Santé 811 in Quebec; other numbers in Manitoba, the Northwest Territories and Nunavut). Checked 12 October 2026. Link
  20. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Canadian Adult Obesity Clinical Practice Guideline: Pharmacotherapy for Obesity Management in Adults, 2025 update. Obesity Canada, Version 3, 11 August 2025 (recommendations 1–13; six medicines approved for obesity; off-label use discouraged; pregnancy). PDF
  21. Apotex. Sevmia (semaglutide injection) Product Monograph, date of authorization 29 June 2026 (“SEVMIA can be prescribed only for 1 mg once weekly dosing. Alternative products are needed to achieve doses of Semaglutide Injection exclusive of the 1 mg dose”; 1 pen of 4 doses; storage). PDF

Last checked 12 Oct 2026 · Next review due 12 Apr 2027 · Report an error

How this post was made. Written by the GLP Guidebook team from the sources above. It’s general information, not medical advice. Talk to your family doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write